Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $340

Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $380 to $340.